₹2,110.75 31.25 (1.50%)
10:00 AM, 7-Jan-2026₹2,103.50 28.90 (1.39%)
09:49 AM, 7-Jan-2026BSE : 532296
NSE : GLENMARK
Sector : Health care
ISIN Code : INE935A01035
Last Updated: 07-Jan-2026 | 10:00 AM IST
| Market Cap (₹ Cr) | 59,565 |
Traded Value (₹ Cr) | 2.72 |
Volume (Shares) | 12,889 |
Face Value (₹) | 1 |
52-Week High (₹) | 2,286.15 |
52-Week High Date | 11-Jul-2025 |
52-Week Low (₹) | 1,274.70 |
52-Week Low Date | 28-Feb-2025 |
All Time High (₹) | 2,286.15 |
All Time High Date | 11-Jul-2025 |
All Time Low (₹) | 1.89 |
All Time Low Date | 10-Feb-2000 |
| PARAMETER | VALUES |
|---|---|
| Market Cap (₹ Cr) | 59,361 |
| EPS - TTM (₹) [C] | 35.78 |
| P/E Ratio (X) [C] | 58.79 |
| Face Value (₹) | 1 |
| Latest Dividend (%) | 250.00 |
| Latest Dividend Date | 03-Oct-2025 |
| Dividend Yield (%) | 0.12 |
| Book Value Share (₹) [C] | 339.54 |
| P/B Ratio (₹) [C] | 6.20 |
| Scheme Name | Amount Invested (₹ Cr) | No Of Shares | Net Asset (%) |
|---|---|---|---|
| UTI-Value Fund - Direct (G) | 167.90 | 8,25,000 | 1.65 |
| UTI-Value Fund (G) | 167.90 | 8,25,000 | 1.65 |
| UTI-Value Fund (IDCW) | 167.90 | 8,25,000 | 1.65 |
| UTI-Value Fund - Direct (IDCW) | 167.90 | 8,25,000 | 1.65 |
| UTI-Mid Cap Fund - Direct (G) | 122.11 | 6,00,000 | 1.02 |
| UTI-Mid Cap Fund (G) | 122.11 | 6,00,000 | 1.02 |
| UTI-Mid Cap Fund (IDCW) | 122.11 | 6,00,000 | 1.02 |
| UTI-Mid Cap Fund - Direct (IDCW) | 122.11 | 6,00,000 | 1.02 |
| UTI-Nifty200 Momentum 30 Index Fund (G) | 109.99 | 5,40,433 | 1.27 |
| UTI-Nifty200 Momentum 30 Index Fund - Direct (G) | 109.99 | 5,40,433 | 1.27 |
Load more
| Date | Broker | Action | Prices(₹) | Report |
|---|---|---|---|---|
| 11-Jul-2025 | Motilal Oswal | Buy | 2,430 | |
| 27-Dec-2024 | Geojit Financial Services | Accumulate | 1,720 | |
| 28-May-2024 | Edelweiss Securities | Hold | 1,200 |
| Today's Low/High (₹) | 2,070.70 2,114.00 |
| Week Low/High (₹) | 2,011.00 2,114.00 |
| Month Low/High (₹) | 1,892.70 2,114.00 |
| Year Low/High (₹) | 1,275.50 2,285.00 |
| All time Low/High (₹) | 1.89 2,285.00 |
| Period | BSE | NSE | SENSEX | NIFTY |
|---|---|---|---|---|
| 1 Week | 3.32% | 3.36% | -0.33% | -0.06% |
| 1 Month | 7.01% | 6.87% | -0.90% | -0.27% |
| 3 Month | 7.19% | 7.18% | 3.68% | 4.01% |
| 6 Month | 12.95% | 13.09% | 1.80% | 2.57% |
| 1 Year | 28.14% | 28.10% | 8.62% | 10.15% |
| 3 Year | 397.75% | 397.28% | 41.81% | 46.22% |
Chairman / Executive Director / M D / Promoter : Glenn Saldanha
ED / WTD / Promoter : Cheryl Pinto
ED / President / Global CFO : Anurag Mantri
Non Executive Director : B E Saldanha
Independent Non Exe. Director : Sona Saira Ramasastry
Independent Non Exe. Director : Dipankar Bhattacharjee
Independent Non Exe. Director : V R Iyer
Independent Non Exe. Director : Pradeep Kumar Sinha
Company Sec. & Compli. Officer : Harish Kuber
Registered Office: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road,Mumbai,Maharashtra-400026 Ph: 91-22-40189999
1. What's the Glenmark Pharmaceuticals Ltd share price today?
Glenmark Pharmaceuticals Ltd share price was Rs 2,110.75 at 10:00 AM IST on 7th Jan 2026. Glenmark Pharmaceuticals Ltd share price was up by 1.50% over the previous closing price of Rs 2,079.50. Glenmark Pharmaceuticals Ltd share price trend:
2. How can I quickly analyse the performance of the Glenmark Pharmaceuticals Ltd stock?
The performance of the Glenmark Pharmaceuticals Ltd stock can be quickly analysed on the following metrics:
3. What is the market cap of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a market capitalisation of Rs 59,565 crore.
4. What is Glenmark Pharmaceuticals Ltd's 52-week high/low share price?
The Glenmark Pharmaceuticals Ltd’s 52-week high share price is Rs 2,286.15 and 52-week low share price is Rs 1,274.70.
5. Is the Glenmark Pharmaceuticals Ltd profitable?
On a consolidated basis, Glenmark Pharmaceuticals Ltd reported a profit of Rs 610.43 crore on a total income of Rs 6,247.50 crore for the quarter ended 2025.
6. Which are Glenmark Pharmaceuticals Ltd’s peers in the Health care sector?
Glenmark Pharmaceuticals Ltd’s top 5 peers in the Health care sector are Alkem Lab, Laurus Labs, Abbott India, Glenmark Pharma., Biocon, Glaxosmi. Pharma, Ipca Labs..
7. Who owns how much in Glenmark Pharmaceuticals Ltd?
Key changes to the Glenmark Pharmaceuticals Ltd shareholding are as follows: